Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

611

Next Previous
Drug Profile

611

Alternative Names: Anti-IL4Ra antibody; Recombinant humanized anti-IL-4 receptor alpha IgG4 monoclonal antibody; SSGJ-611

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer Sunshine Guojian Pharmaceutical
  • Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase III Chronic obstructive pulmonary disease; Rhinosinusitis

Most Recent Events

  • 21 Aug 2026 Phase-I development in Atopic-dermatitis (In volunteers) is ongoing in USA (SC, Injection) (Sunshine Guojian Pharmaceutical pipeline, August 2026)
  • 17 Aug 2026 Sunshine Guojian Pharmaceutical plans a phase III trial for Atopic dermatitis (In children) in China (SC) in September 2026 (NCT07767253)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Atopic-dermatitis(In volunteers) in USA (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top